TY - JOUR T1 - Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial JF - medRxiv DO - 10.1101/2020.09.23.20199604 SP - 2020.09.23.20199604 AU - Jerald Sadoff AU - Mathieu Le Gars AU - Georgi Shukarev AU - Dirk Heerwegh AU - Carla Truyers AU - Anne Marit de Groot AU - Jeroen Stoop AU - Sarah Tete AU - Wim Van Damme AU - Isabel Leroux-Roels AU - Pieter-Jan Berghmans AU - Murray Kimmel AU - Pierre Van Damme AU - Jan de Hoon AU - Williams Smith AU - Kathryn E. Stephenson AU - Dan H. Barouch AU - Stephen C. De Rosa AU - Kristen W. Cohen AU - M. Juliana McElrath AU - Emmanuel Cormier AU - Gert Scheper AU - Jenny Hendriks AU - Frank Struyf AU - Macaya Douoguih AU - Johan Van Hoof AU - Hanneke Schuitemaker Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/25/2020.09.23.20199604.abstract N2 - BACKGROUND The ongoing coronavirus disease (COVID)-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be controlled by an efficacious vaccine. Multiple vaccines are in development, but no efficacious vaccine is currently available.METHODS We designed a multi-center phase 1/2a randomized, double-blinded, placebo-controlled clinical study to assesses the safety, reactogenicity and immunogenicity of Ad26.COV2.S, a non-replicating adenovirus 26 based vector expressing the stabilized pre-fusion spike (S) protein of SARS-CoV-2. Ad26.COV2.S was administered at a dose level of 5×1010 or 1×1011 viral particles (vp) per vaccination, either as a single dose or as a two-dose schedule spaced by 56 days in healthy adults (18-55 years old; cohort 1a & 1b; n= 402 and healthy elderly ≥65 years old; cohort 3; n=394). Vaccine elicited S specific antibody levels were measured by ELISA and neutralizing titers were measured in a wild-type virus neutralization assay (wtVNA). CD4+ T-helper (Th)1 and Th2, and CD8+ immune responses were assessed by intracellular cytokine staining (ICS).RESULTS We here report interim analyses after the first dose of blinded safety data from cohorts 1a, 1b and 3 and group unblinded immunogenicity data from cohort 1a and 3. In cohorts 1 and 3 solicited local adverse events were observed in 58% and 27% of participants, respectively. Solicited systemic adverse events were reported in 64% and 36% of participants, respectively. Fevers occurred in both cohorts 1 and 3 in 19% (5% grade 3) and 4% (0% grade 3), respectively, were mostly mild or moderate, and resolved within 1 to 2 days after vaccination. The most frequent local adverse event (AE) was injection site pain and the most frequent solicited AEs were fatigue, headache and myalgia. After only a single dose, seroconversion rate in wtVNA (50% inhibitory concentration - IC50) at day 29 after immunization in cohort 1a already reached 92% with GMTs of 214 (95% CI: 177; 259) and 92% with GMTs of 243 (95% CI: 200; 295) for the 5×1010 and 1×1011vp dose levels, respectively. A similar immunogenicity profile was observed in the first 15 participants in cohort 3, where 100% seroconversion (6/6) (GMTs of 196 [95%CI: 69; 560]) and 83% seroconversion (5/6) (GMTs of 127 [95% CI: <58; 327]) were observed for the 5×1010 or 1×1011 vp dose level, respectively. Seroconversion for S antibodies as measured by ELISA (ELISA Units/mL) was observed in 99% of cohort 1a participants (GMTs of 528 [95% CI: 442; 630) and 695 (95% CI: 596; 810]), for the 5×1010 or 1×1011 vp dose level, respectively, and in 100% (6/6 for both dose levels) of cohort 3 with GMTs of 507 (95% CI: 181; 1418) and 248 (95% CI: 122; 506), respectively. On day 14 post immunization, Th1 cytokine producing S-specific CD4+ T cell responses were measured in 80% and 83% of a subset of participants in cohort 1a and 3, respectively, with no or very low Th2 responses, indicative of a Th1-skewed phenotype in both cohorts. CD8+ T cell responses were also robust in both cohort 1a and 3, for both dose levels.CONCLUSIONS The safety profile and immunogenicity after only a single dose are supportive for further clinical development of Ad26.COV2.S at a dose level of 5×1010 vp, as a potentially protective vaccine against COVID-19.Trial registration number NCT04436276Competing Interest StatementJanssen Pharmaceuticals and the US Army have a cooperative research agreement (Cooperative Research and Development Agreement, CRADA). Under the terms of the agreement, Janssen may provide financial resources to support work; there is no personal financial benefit from the arrangement. JS, MLG, GS, DH, CT, MG, JS, ST, EC, GS, JH, FS, MD, JVH and HS are all employees of Janssen Pharmaceuticals and may be Johnson & Johnson stockholders.Clinical TrialNCT04436276Funding StatementThis project was sponsored by Johnson and Johnson and funded, in part, by the Department of Health and Human Services Biomedical Advanced Research and Development Authority under contract HHS0100201700018C.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed and approved by local ethics committees (Comite d Ethique Hospitalo-Facultaire Sain-Luc, Universite Catholique de Louvain on July 16, 2020) and institutional review boards (IRB) (approval by Advarra IRB on June 29 and July 10, 2020, for New Orleans Center for Clinical Research and Optimal Research sites, respectively)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data referred to in the manuscript will be available. ER -